Drug Interactions Between Psychoactive Substances and Antiretroviral Therapy in Individuals Infected With Human Immunodeficiency and Hepatitis Viruses

References

• Adams H G, Jordan C. Infections in the alcoholic. Med. Clin. North. Am 1984; 68: 179–200
   PubMed Web of Science ®Google Scholar
• Adas F, Betthou F, Picart D. Involvement of cytochrome P450 2E1 in the (omega-1)-hydroxylation of oleic acid in human and rat liver microsomes. J. Lipid. Res 1998; 39: 1210–1219
   PubMed Web of Science ®Google Scholar
• Adkins J C, Noble S. Efavirenz. Drugs 1998; 56(6)1055–1064
   PubMed Web of Science ®Google Scholar
• Ahmadi J. Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. Journal of Substance Abuse Treatment 2003; 24: 217–220
   PubMed Web of Science ®Google Scholar
• AIDS Clinical Trial Group Criteria. Division of AIDS. Table for grading severity of adult adverse experiences. August, 1992
   Google Scholar
• Akerele E O, Levin F, Nunes E, Brady R, Kleber H. Effects of HIV triple therapy on methadone levels. Am. J. Addiction 2002; 11: 308–314
   PubMed Web of Science ®Google Scholar
• Alter M J, Kruszon-Moran D, Nainan O V, McQuillan G M, Gao F, Moyer L A, Kaslow R A, Margolis H S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med 1999; 341: 556–562
   PubMed Web of Science ®Google Scholar
• Anand B S, Velez M. Influence of chronic alcohol abuse on hepatitis C virus replication. Dig. Dis 2000; 18(3)168–171
   PubMed Web of Science ®Google Scholar
• Anand K J, Arnold J H. Opioid tolerance and dependence in Infants and children. Crit. Care Med 1994; 22(2)334–342
   PubMed Web of Science ®Google Scholar
• Azcue M, Neuman M G, Pencharz P. What does bioelectrical impedance spectroscopy (BIS) measure. Human Body Composition, K Ellis, G Eastman. Plenum Press, New York 1993; 121–125
   Google Scholar
• Azrin N H, Acierno R, Kogan E, Donahue B, Besalel V, McMahon P T. Follow-up results of supportive versus behavioral therapy for illicit drug abuse. Behavioral Research & Therapy 1996; 34(1)41–46
   PubMed Web of Science ®Google Scholar
• Azrin N H, McMahon P T, Donahue B, Besalel V, Lapinski K J, Kogan E, Acierno R, Galloway E. Behavioral therapy for drug abuse: a controlled treatment outcome study. Behavioral Research & Therapy 1994; 32(8)857–866
   PubMed Web of Science ®Google Scholar
• Backmund M, Meyer K, Von Zielonka M, Einchlenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188–192
   PubMed Web of Science ®Google Scholar
• Backmund M, Meyer K, Wachtler M, Einchlenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur. J. Epidemiol 2003; 18: 563–568
   PubMed Web of Science ®Google Scholar
• Ball A. Drugs use in HIV AIDS. Summary papers given in Track D of the XIIth International AIDS Conference, Durban, South Africa, July 9–14., 2000, 9–14
   Google Scholar
• Bando M, Ohno S, Oshikawa K, Takahashi M, Okamoto H, Sugiyama Y. Infection of TT virus in patients with idiopathic pulmonary fibrosis. Respir. Med 2001; 95(12)935–942
   PubMed Web of Science ®Google Scholar
• Barner A, Myers M. Nevirapine and rashes. Lancet 1998; 351: 1133
   PubMed Web of Science ®Google Scholar
• Barre-Sinoussi F, Chermann J C, Rey F, Nugeyre M T, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868–871
   PubMed Web of Science ®Google Scholar
• Barve S S, Kelkar S V, Gobejishvilli L, Joshi-Barve S, McClain C J. Mechanisms of alcohol-mediated CD4+ T lymphocyte death: relevance to HIV and HCV pathogenesis. Front Biosci 2002; 7: 1689–1696
   PubMed Web of Science ®Google Scholar
• Bastos F L, Strathdee S A, Derrico M, Pna F. Drug use and the spread of HIV AIDS in South America and the Carribean. Drugs: Education, Prevention and Policy 1999; 6(1)29–50
   Web of Science ®Google Scholar
• Bataller R, Brenner D A. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver Dis 2001; 21(3)437–451
   PubMed Web of Science ®Google Scholar
• Batel P. The treatment of alcoholism in France. Drug Alcohol Depend 1995; 39((Suppl. 1))S15–S21
   PubMedGoogle Scholar
• Batel P, Pessione F, Maitre C, Rueff B. Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction 1995; 90: 997–980
   PubMed Web of Science ®Google Scholar
• Bates D W. Drugs and adverse drug reactions: how worried should we be? JAMA 1998; 279: 1200–1205
   Google Scholar
• Bates D W, Cullen D J, Laird N, Petersen L A, Small D S, Servi D, Laffel G. Incidence of adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995; 274: 29–34
   PubMed Web of Science ®Google Scholar
• Batey R G, Burns T, Bensonn R J, Blyth K. Alcohol consumption and the risk of cirrhosis. Med. J. Aust 1992; 156: 413–416
   PubMed Web of Science ®Google Scholar
• Bautista A P. Free radicals, chemokines, and cell injury in HIV-1 and SIV infections and alcoholic hepatitis. Free Radic. Biol. Med 2001; 15;31(12)1527–1532
   Web of Science ®Google Scholar
• Bayard P J, Berger T G, Jacogson M A. Drug hypersensitivity reactions and human immunodeficiency disease. J. Acquir Immune Defic. Syndr 1992; 5(12)1237–1257
   PubMed Web of Science ®Google Scholar
• Beach J W. Chemotherapeutic agents for human immunodeficiency virus infection: mechansim of action, pharmacokinetics, metabolism, and adverse reactions. Clinical Therapeutics 1998; 20: 2–25
   PubMed Web of Science ®Google Scholar
• Beal J E, Olson R, Laubenstein L. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manage 1995; 10: 89–97
   PubMed Web of Science ®Google Scholar
• Beasley R P. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942–1956
   PubMed Web of Science ®Google Scholar
• Bedossa P, Paradis V. Tranforming growth factor-b (TGF-b): A key role in liver fibrogenesis. J. Hepatology 1995; 22(2 Suppl.)37–42
   PubMedGoogle Scholar
• Bellentani S, Pozzato G, Saccoccio G. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysus study. Gut 1999; 44: 874–880
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M D, Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard J. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The MULTIVIRC group. Hepatology 1999; 30(4)1054–1057
   PubMed Web of Science ®Google Scholar
• Berde C, Ablin A, Glazer J. American Academy of Pediatrics report of the subcommittee on Disease-Related Pain in Childhood Cancer. Pediatrics 1990; 86(5 Pt 2)818–825
   PubMedGoogle Scholar
• Berenguer M, Terrault N A, Piatak M, Yun A, Kim J S. P, Lau J Y. N, Lake J R, Roberts J P, Ascher N A, Wright T L. Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology 1996; 111: 1569–1575
   PubMed Web of Science ®Google Scholar
• Berger J R, Pall L, Winfield D. Effect of anabolic steroids on HIV-related wasting myopathy. South Med. J 1993; 86: 865–866
   PubMed Web of Science ®Google Scholar
• Bergheim I, Parlesak A, Dierks C, Bode J C, Bode C. Nutritional deficiencies in German middle-class male alcohol consumers: relation to dietary intake and severity of liver disease. Eur. J. Clin. Nutr 2003; 57(3)431–438
   PubMed Web of Science ®Google Scholar
• Black M, Mitchell J R, Zimmerman H J, Ishak K G, Epler G R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289–302
   PubMed Web of Science ®Google Scholar
• Bode J C, Alscher D M, Wisser H, Bode C. Detection of hepatitis C virus antibodies and hepatitis C virus RNA in patients with alcoholic liver disease. Alcohol Alcohol 1995; 30(1)97–103
   PubMed Web of Science ®Google Scholar
• Bodsworth N J, Cunningham P, Kaldor J. Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HIV-1 infection and injecting drug use but not sexual behavior. Genitourin Med 1996; 72: 118–122
   PubMedGoogle Scholar
• Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch. Intern. Med 2000; 160(22)3365–3373
   PubMed Web of Science ®Google Scholar
• Brady M. Commentaries on Landau's: The prospects of harm reduction approach among indigenous people in Canada: harm reduction—already happening?. Drugs Alcohol Rev 1996; 15: 407–409
   Web of Science ®Google Scholar
• Brenner D A. Moderate alcohol drinking: effects on the heart and liver. Gastroenterology 2000; 119(5)1333–1339
   PubMed Web of Science ®Google Scholar
• Brenner D A, Waterboer T, Sung Kyu choi, Lindquist J N, Stefanovic B, Burchardt E, Yamauchi M, Gillan A, Rippe R A. New aspects of hepatic fibrosis. J. Hepatol 2000; 32(Suppl. 1)32–38
   PubMedGoogle Scholar
• Bresters D, Mauser-Bunschoten E P, Reesink H W. Sexual transmission of hepatitis C virus. Lancet 1993; 342: 210–211
   PubMed Web of Science ®Google Scholar
• Brillanti S, Masci C, Siringo S, Di Febo G, Miglioli M, Barbara L. Serological and histological aspects of hepatitis C virus infection in alcoholic patients. J Hepatol 1991; 13(3)347–350
   PubMed Web of Science ®Google Scholar
• Brinkman K, Smeitink J A, Romijn J A, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112–1115
   PubMed Web of Science ®Google Scholar
• Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA (“ecstasy”). JAMA 1987; 258: 780
   PubMed Web of Science ®Google Scholar
• Budney A J, Kandel D B, Cherek D R, Martin B R, Stephens R S, Roffman R. Marijuana use and dependence. Drug and Alcohol Dependence 1997; 45: 1–11
   PubMed Web of Science ®Google Scholar
• Burrows D. Contradictory strategies: HIV and drugs. National AIDS Bulletin 1996; 10(1)20–21
   Google Scholar
• Burrows D, Holmes D, Schwalbe N. Drug use injects HIV AIDS into former Soviet Union. AIDS Links 2002; 2
   Google Scholar
• Burrows D, Rhodes T, Trautman F, Bilj M, Stimson G. Responding to HIV infection associated with drug injecting in Eastern Europe. Drug Alcohol Rev 1998; 17: 453–463
   PubMed Web of Science ®Google Scholar
• Butler T, Dolan K, Ferson M, McGuiness L, Brown P, Robertson P. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Med J Australia 1997; 166: 127–130
   PubMed Web of Science ®Google Scholar
• Caldwell S H, Li X, Rourk R M, Millar A, Sosnowski K M, Sue M, Barritt A S, McCallum R W, Schiff E R. Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am. J. Gastroenterol 1993; 88(7)1016–1021
   PubMed Web of Science ®Google Scholar
• Cameron R G, Neuman M G. Novel Morphologic findings in alcoholic liver disease. Clin. Biochem 1999; 32: 579–584
   PubMed Web of Science ®Google Scholar
• Caredda F, Rossi E, d'Arminio Monteforte A. Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome. J. Infect. Dis 1985; 151: 925–928
   PubMed Web of Science ®Google Scholar
• Carpenter C C, Cooper D A, Fischl M A. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-–USA Panel. JAMA 2000; 283: 381–391
   PubMed Web of Science ®Google Scholar
• Carr A, Cooper D A. Pathogenesis and management of HIV-associated drug hypersensitivity. AIDS Clin. Rev 1995;  65–97
   Google Scholar
• Carr A, Cooper D A. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423–1430
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Chisholm D J, Cooper D A. Pathogenesisi of HIV-protease inhibitor associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998; 351: 1881–1883
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Thorisdottir A, Kaufmann G R, Chisholm J, Cooper D A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093–2099
   PubMed Web of Science ®Google Scholar
• Carruthers S, Loxley W. Hepatitis C and young drug users: are they about to join the epidemic? Australian J Public Health 1995; 19(4)421–424
   Google Scholar
• Carruthers S J, Loxley W M, Phillips M, Bevan J S. The Australian study of HIV and IDU, part 2; predicting exposure to hepatitis C and B. Drug Alcohol Rev 1997; 16: 215–220
   PubMed Web of Science ®Google Scholar
• Casado J L, Dronda F, Hertogs K. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. AIDS Res. Hum. Retroviruses 2001; 17: 93–98
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommendations for protection against viral hepatitis. MMWR 1985; 34: 313–335
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm. Rep. 1998; 47(RR-19: 1–39
   Google Scholar
• Centers for Disease Control and Prevention. HIV AIDS update a glance of HIV epidemics. 2002a, Available atwww.cdc.gov/hiv/pubs/facts.htm accessed November 29
   Google Scholar
• Center for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV, MMWR, 2002b; 51(RR-7)1–55
   Google Scholar
• Centers for Disease Control and Prevention. National Center for Infectious Diseases. Viral hepatitis C fact sheet. Available at. 2002, www.cdc.gov/ncdod/diseases/hepatitis/c.fact.htm accessed on November 29
   Google Scholar
• Chariot P, Drogou I, Lacroix-Szmania I. Zidovuline induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depleation. J. Hepatol 1999; 30: 156–160
   PubMed Web of Science ®Google Scholar
• Chedid A, Mendenhall C L, Garside P. Prognostic factors in alcoholic liver disease. Am. J. Gastroenterol 1991; 82: 210–216
   Google Scholar
• Chen C J, Liang K Y, Chang A S, Chang Y C, Lu S N, Liaw Y F, Chang W Y. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 1991; 13: 398–406
   PubMed Web of Science ®Google Scholar
• Chevillotte G, Durbec J P, Gerolami A, Berthezene P, Bidart J M, Camatte R. Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis: an epidemiologic study. Gastroenterology 1983; 85: 141–145
   PubMed Web of Science ®Google Scholar
• Choi M. Y., Lee S. S, Mac W. Y., Chan W. M. Low rates of needle-sharing in drug user attending the methadone clinics. Vancouver. Proceedings of the XI International Conference on AIDS. 1996
   Google Scholar
• Choo Q L, Kuo G, Weiner A J. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244(4902)359–362
   PubMed Web of Science ®Google Scholar
• The Global Burden of Disease The Global Burden of Disease, J. L. Murray Christopher, D. Lopez Alan. World Public Health, and The World Bank, Geneva 1996; volume 1: 311
   Google Scholar
• Clark W H. A new era in opioid dependency treatment: recent law allows qualified physicians to provide care in office setting. Postgraduate Medicine 2001; 109: 6
   Web of Science ®Google Scholar
• Clarke S M, Mulcahy F M. Antiretroviral therapy for drug users. Intl. J. STD AIDS 2000; 11: 627–631
   PubMed Web of Science ®Google Scholar
• Coelho-Little M E, Jeffers L J, Bernstein D E, Goodman J J, Reddy K R, de Medina M, Li X, Hill M, La Rue S, Schiff E R. Hepatitis C virus in alcoholic patients with and without clinically apparent liver disease. Alcohol Clin Exp Res 1995; 19(5)1173–1176
   PubMed Web of Science ®Google Scholar
• Colin J F, Cuzais-Hatem D, Loriot M A. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29(4)1306–1310
   PubMed Web of Science ®Google Scholar
• Collier J, Chapman R. Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues. BioDrugs 2001; 15(4)225–238
   PubMed Web of Science ®Google Scholar
• Collura J M, Kraus D M. New pediatric antiretroviral agents. J. Pediatr. Health Care 2000; 14(4)183–190
   PubMedGoogle Scholar
• Conte D, Fraquella M, Prati D. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31: 751–755
   PubMed Web of Science ®Google Scholar
• Conry-Cantilena C, VanRadden M, Gibble J. Routes on infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N. Engl. J. Med 1996; 334: 1691–1696
   PubMed Web of Science ®Google Scholar
• Cook R T. Alcohol abuse, alcoholism, and damage to the immune system–-a review. Alcohol Clin. Exp. Res 1998; 22(9)1927–1942
   PubMed Web of Science ®Google Scholar
• Costigan G., Crofts N., Reid G. eds. Drug use and HIV vulnerability. In: Manual for Drug Reducing Harm Asia, the Centre for Harm Reduction. Macfarlane Burnet Centre for Medical Research and Asian Harm Reduction Network. Chaingmai, Thailand 2003
   Google Scholar
• Cribier B, Rey D, Scmitt C, Lang J M, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9: 1131–1136
   PubMed Web of Science ®Google Scholar
• Crippin J S, McCashland T, Terrault N, Sheiner P, Charlton M R. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350–355
   PubMed Web of Science ®Google Scholar
• Dallabetta G, Gavrilin S. Assessment of the HIV situation in selected sites in Kyrgzstan, Uzbekistan and Kazakhstan. Report prepared for the USAID Regional Mission for Central Asia. 2001
   Google Scholar
• Darby S, Ewart D, Giangrande P, Spooner R, Rizza C, Dusheiko G, Lee C, Ludlam C, Preston F. Mortality from liver cancer and liver disease in haemophiliac men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425–1431
   PubMed Web of Science ®Google Scholar
• Davidson D, Swift R, Fitz E. Naltrexone increaseas the latency to drink alcohol in social drinkers. Alcohol Clin. Exp. Res 1996; 20: 732–739
   PubMed Web of Science ®Google Scholar
• Deeks S G, Smith M, Holodniy M. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277(2)145–153
   PubMed Web of Science ®Google Scholar
• Delage G, Infante-Rivard C, Chiavetta J A. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study. Gastroenterology 1999; 116: 893–899
   PubMed Web of Science ®Google Scholar
• Detels R, Munoz A, McFarlane G, Kingsley L A, Margolick J B, Giorgi J, Schrager L K, Phair J P, for the Multicenter AIDS Cohort Study Investigators. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998; 280: 1497–1503
   PubMed Web of Science ®Google Scholar
• Dieterich D T. Gastrointestinal manifestations of HIV disease. Textbook of AIDS. Baltimore, S Broder, T C Merigan, D Bolognesi. Williams & Wilkins. 1993
   Google Scholar
• Donahue J G, Nelson K E, Munoz A. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am. J. Epidemiol 1996; 134: 1206–1211
   Google Scholar
• Dowsett G.W., Turney L., Woolcock G., Thomson N. Hepatitis C Prevention Education for Injecting Drug Users in Australia. A Research Report. Commonwealth Department of Health and Aged Care, SydneyAustralia 1999
   Google Scholar
• Dubowski K M. Human pharmacokinetics of ethanol. I. Peak blood concentrations and elimination in male and female subjects. Alcohol Technical Reports 1976; 5: 55–63
   Google Scholar
• Dufour M C. What is moderate drinking? Defining “drinks” and drinking levels. Alcohol Res. Health 1999; 23: 5–14
   PubMedGoogle Scholar
• Duguay L, Coutu D, Hetu C, Joly J G. Inhibition of liver regeneration by chronic alcohol administration. Gut 1982; 23(1)8–13
   PubMed Web of Science ®Google Scholar
• DuPont H L, Marshall G D. HIV-associated diarrhoea and wasting. Lancet 1995; 346: 352–356
   PubMed Web of Science ®Google Scholar
• Eap C B, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet 2002; 41(14)1153–1193
   PubMed Web of Science ®Google Scholar
• Eneanya D I, Bianchine J R, Duran D O, Andresen B D. The actions of metabolic fate of disulfiram. Annu. Rev. Pharmacol. Toxicol 1981; 21: 575–596
   PubMed Web of Science ®Google Scholar
• Esteban J I, Esteban R, Viladomiu L. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989; 2: 294–297
   PubMed Web of Science ®Google Scholar
• Esteban J I, Lopez-Talavera J C, Genesca J. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann. Intern. Med 1991; 115: 443–449
   PubMed Web of Science ®Google Scholar
• Evans W E, McLeod H L. Pharmacogenomics drug disposition, drug targets and effects. N. Engl. J. Med 2003; 348: 538–549
   PubMed Web of Science ®Google Scholar
• Everson G T. Treatment of patients with hepatitis C on the waiting list. Liver Transpl 2003; 9: S90–S94
   Web of Science ®Google Scholar
• Eyster M E, Alter H J, Aledort L M. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann. Intern. Med 1991; 115: 764–768
   PubMed Web of Science ®Google Scholar
• Eyster M E, Diamondstone L S, Lien J M, Ehmann C, Quan S. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes 1993; 6: 602–610
   PubMed Web of Science ®Google Scholar
• Eyster M E, Fried M W, Di Bisceglie A M, Goedert J J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994; 84: 1020–1023
   Google Scholar
• Ezzati M, Lopez A D, Rodgers A, Vander Horn S, Murray C J. L. and the Comparative Risk Assessment Collaborating Group. (2002). Selected major risk factors and global and regional burden of disease. Lancet, 360: 1347–1360
   PubMedGoogle Scholar
• Farrell G C. Hepatocellular carcinoma after sustained response to interferon in noncirrhotic hepatitis C: flaws in the cure, or a clue to the flaws?. J. Gastroenterol. Hepatol 1999; 14(9)833–837
   PubMed Web of Science ®Google Scholar
• Fattovich G, Boscaro S, Noventa F. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J. Infect. Dis 1987; 155: 931–935
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Christensen E. and the European Concerted Action on Viral Hepatitis (Eurohep). (2000). Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut, 46: 420–426
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112(2)463–472
   PubMed Web of Science ®Google Scholar
• Fauci A S, Bartlett J G, Goosby E P, Smith M D. Panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Federal Register 2000
   Google Scholar
• Ferm V H, Willhite C, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 1978; 17(1)93–101
   PubMedGoogle Scholar
• Fiore R J, Potenza D, Monno L, Appice A, DiStefano M. Detection of HCV RNA in serum and seminal fluid from HIV-1 co-infected intravenous drug addicts. J. Med. Virol 1995; 46: 364–367
   PubMed Web of Science ®Google Scholar
• Food and Agriculture Organization of the United Nations (FAO). The Sixth World Food Survey. Rome, FAO 1996; v–vi
   Google Scholar
• Forns X, Bukh J. The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin. Liver Dis 1999; 3(4)693–716
   PubMedGoogle Scholar
• Foster G R. Hepatitis C virus infection: quality of life and side effects of treatment. J. Hepatol 1999; 31(Suppl. 1)250–254
   PubMedGoogle Scholar
• Foster G R, Goldin R, Thomas H C. Chronic hepatitis C virus infection causes a significant reduction in quality of life. Hepatology 1998; 27(1)209–212
   PubMed Web of Science ®Google Scholar
• Fox M, Minot A S, Liddle G W. Oxandrolone: a potent anabolic steroid of novel chemical configuration. J. Clin. Endocrinol Metab 1962; 22: 921–924
   PubMed Web of Science ®Google Scholar
• French S W, Nash J, Shitabata P, Kachi K, Hara C, Chedid A. Pathology of alcoholic liver disease. Semin. Liver Dis 1993; 13: 154–169
   PubMed Web of Science ®Google Scholar
• Fried M W. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36(Suppl. 1)S237–S244
   PubMed Web of Science ®Google Scholar
• Fried M W, Shiffman M L, Reddy K R, Smith C, Marinos G, Goncales F L, Jr, Haussinger D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med 2002; 347: 975–982
   PubMed Web of Science ®Google Scholar
• Friedman S L. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N. Engl. J. Med 1993; 328: 1828–1835
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Uemura M, Kojima H, Ishii Y, Ann T, Sakurai S, Okuda K, Noguchi K, Adachi S, Kitano H, Hoppo K, Higashino T, Takaya A, Fukui H. and the Nara Liver Study Group. (1999). Prognostic factors in severe alcoholic liver injury. Alcoholism Clin. Exp. Res, 24(3 suppl.)33–38
   Google Scholar
• Furqaan A, Jacobson I M, Hargrave T, Lawitz E, Migicovsky B, Reddy V, Terrault N, Brown Jr R S. Brass C. Diabetus mellitus of a new onset during pegylated interferon and ribavirin therapy for chronic hepatitis C: observation from the WIN-R trial. Hepatology, 38(Suppl. 1)1190
   Google Scholar
• Gabele E, Brenner D A, Rippe R A. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. Front Biosci 2003; 1: D69–77
   Google Scholar
• Gaeta G B, Stroffolini T, Chiaramonte M. Chronic hepatitis D: a vanishing disease? An Italian multinational study. Hepatology 2000; 32: 824–827
   PubMed Web of Science ®Google Scholar
• Garcia J M, Marugan R B, Garcia G M, Lindeman M L, Abete J F, Terron S D. TT virus infection in patients with chronic hepatitis B and response of TTV to lamivudine. World J. Gastroenterol 2003; 9(6)1261–1264
   PubMed Web of Science ®Google Scholar
• Garcia-Samaniego J, Soriano V, Castilla J, Bravo R, Moreno A. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The American Journal of Gastroenterology 1997; 92: 1130
   PubMed Web of Science ®Google Scholar
• Garfein R S, Doherty M C, Monterroso E R. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol 1998; 18(Suppl. 1)S11–S19
   PubMedGoogle Scholar
• Garfein R S, Vlahov D, Galai N. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health 1996; 86: 655–661
   PubMed Web of Science ®Google Scholar
• Gatch M B, Lal H. Pharmacological treatment of alcoholism. Prog. Neur. Psychopharmacol. Biol. Psychiat 1998; 22: 917–944
   PubMed Web of Science ®Google Scholar
• Gelb A M, Richman B L, Peyser N P. Alcohol used in methadone maintenance clinics. Am. J. Drug Alcohol Abuse 1979; 6: 367–373
   PubMed Web of Science ®Google Scholar
• Glue P, Fang J W, Rouzier-Panis R, Raffanel C, Sabo R, Gupta S K. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther 2000a; 68(5)556–567
   PubMed Web of Science ®Google Scholar
• Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta S K, Salfi M. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000b; 32(3)647–653
   PubMed Web of Science ®Google Scholar
• Golia P. Pharmacodynamics and pharmacikinetics of hepatitis C virus (HCV and pegylated interferon alpha 2 b in human immunodeficiency virus (HIV) co-infected patients. Hepatology 2003; 38(Suppl. 1)385
   PubMedGoogle Scholar
• Gordon S C, Patel A H, Kulesza G W. Lack of evidence for the heterosexual transmission. Am. J. Gastroenterol 1992; 87: 1849–1851
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D, Rolfe A. Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2000; 60: 275–286
   PubMed Web of Science ®Google Scholar
• Gourevitch M N, Freidland G H. Interactions between methadone and medications used to treat HIV infection: a review. The Mount Sinai J. Med 2000; 67(5 and 6)429–436
   PubMedGoogle Scholar
• Graham C S, Baden L R, Yu E, Mrus J M, Carnie J, Heeren T, Koziel M J. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis 2001; 33: 562–569
   PubMed Web of Science ®Google Scholar
• Graham K, Wilsnack R, Dawson D. Vogeltanz N: should alcohol consumption measures be adjusted for gender differences?. Addiction 1998; 93(8)1137–1147
   PubMed Web of Science ®Google Scholar
• Granovsky M O, Minkoff H L, Tess B H. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 1998; 102: 355–359
   PubMed Web of Science ®Google Scholar
• Green J, Jaffe J H. Alcohol use in the opiate use cycle of the heroin addict. J. Studies Alcohol 1978; 38: 1274–1293
   Google Scholar
• Gruchalla R S. Drug metabolism, danger signals, and drug-induced hypersensitivity. J. Allergy Clin. Immunol 2001; 108: 475–488
   PubMed Web of Science ®Google Scholar
• Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection. Available at. 2001, http://www.aidsinfo.nih.gov accessed February 5
   Google Scholar
• Gulick R M, Mellors J W, Havlir D. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med 1997; 337: 734–739
   PubMed Web of Science ®Google Scholar
• Hadziyannis S J, Sette H, Morgan T R, Balan V, Diago M, Marcellin P, Ramadori G. Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann. Intern. Med 2004; 140: 346–355
   PubMed Web of Science ®Google Scholar
• Hassoba H M, Pessoa M G, Terrault N A, Lewis N J, Hayden M, Hunt J C, Lou S C, Wright T L. Anti-envelope antibodies are protective against GBV-C reinfection: evidence from the liver transplant model. J. Med. Virol 1998; 56: 253–258
   PubMed Web of Science ®Google Scholar
• Hassoba H M, Terrault N A, El-Gohary A M, Scheffel C, Jou C, Brackett J, Hunt J, Lou S C, Wright T L. Antibody to GBV-C second envelope glycoprotein (GBV-C anti E2): is it a marker for immunity?. J Med Virol 1997; 53: 354–360
   PubMed Web of Science ®Google Scholar
• Hauser P M, Blanc D S, Bille J, Nahimana A, Francioli P. The impact of co-infection with hepatatis C virus and HIV on the tolerability of antiretroviral therapy. J. of Acquir Immune Defic. Syndr 2000; 14: 463–464
   Google Scholar
• Health Canada. HIV and AIDS in Canada: Surveillance Report to December 31, 1999. Division of HIV AIDS Surveillance, Bureau of HIV AIDS, STD and TB, Laboratory Centre for Disease Control. Minister of Public Works and Government Services Canada. 2000
   Google Scholar
• Heathcote E J, Shiffman M L, Cooksley W G, Dusheiko G M, Lee S S, Balart L, Reindollar R. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673–1680
   PubMed Web of Science ®Google Scholar
• Hershow R C, Kalish L A, Sha B. Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission. Sex Transm Dis 1998; 25: 527–532
   PubMed Web of Science ®Google Scholar
• Hetherington S, Steel H, Naderer O, Cutrell A, Powell W, Sykes R. Hypersensitivity reactions during therapy with abacavir: analysis of 636 cases for clinical presentation and risk factors. Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, January 30–February 2, 2000. Abstract 60, 2000
   Google Scholar
• Hisada M, O’Brien T R, Rosenberg P S, Goedert J J. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with haemophilia. J Infect Dis 2000; 181: 1475–1478
   PubMed Web of Science ®Google Scholar
• Hogg R, Cahn P, Katabira E T. Time to act: global apathy towards HIV? AIDS is a crime against humanity. Lancet 2002; 360: 1710–1711
   PubMed Web of Science ®Google Scholar
• Hogg R S, Yip B, Kully C, Craib K, O'Shaughnessy M V, Schechter M T, Montaner J S. G. Improved survival among HIV-infected patients after the initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160(5)659–665
   PubMed Web of Science ®Google Scholar
• Hoggard P G, Kewn S, Barry M G, Khoo S H, Back D J. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41: 1231–1236
   PubMed Web of Science ®Google Scholar
• Homman C, Krogsgaard K, Pederson C, Anderson P, Nielsen J O. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advances HIV infection. J Aquir Immune Defic Syndr 1991; 4: 416–420
   PubMed Web of Science ®Google Scholar
• Hommes M J, Romijn J A, Godfried M H. Increased resting energy expenditure in human immunodeficiency virus-infected men. Metabolism 1990; 39: 1186–1190
   PubMed Web of Science ®Google Scholar
• Hoofnagle J H. Therapy of viral hepatitis. Digestion 1998; 59(5)563–578
   PubMed Web of Science ®Google Scholar
• Horowitz J H, Rypins E B, Henderson J M. Evidence for impairment of transsulfuration pathway in cirrhosis. Gastroenterology 1981; 81: 668–675
   PubMed Web of Science ®Google Scholar
• Housset C, Pol S, Carnot F. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992; 15: 578–592
   PubMed Web of Science ®Google Scholar
• ICH-GCP International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. 1997 CFR & ICH Guidelines1st. Barnett International PAREXEL, , PA 1997; 1
   Google Scholar
• Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M. A multiviariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47–53
   PubMed Web of Science ®Google Scholar
• Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F, Riche C. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metabolism and Disposition 1998; 26(3)257–260
   PubMed Web of Science ®Google Scholar
• Ishak K G, Zimmerman H, Ray M B. Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. Alc Clin Exp Res 1991; 15: 45–66
   PubMed Web of Science ®Google Scholar
• Itri L M. The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety. Semin Oncol 2002; 29(Suppl. 8)81–87
   PubMed Web of Science ®Google Scholar
• Jacobson-Brown P, Neuman M G. Immunopathogenesis of hepatitis C viral infection: Th1 Th2 responses and the role of cytokines. Clin Biochem 2001; 34(3)167–171
   PubMed Web of Science ®Google Scholar
• Jarvelainen H A, Orpana A, Perola M. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology 2001; 33: 1148–1153
   PubMed Web of Science ®Google Scholar
• Jerrells T R, Sibley D A, Slukvin II, Mitchell K.A. Effects of ethanol consumption on mucosal and systemic T-cell-dependent immune responses to pathogenic microorganisms. Alcohol Clin Exp Res 1998; 22(5 Suppl.)212S–215S
   Web of Science ®Google Scholar
• Jick H. Adverse drug reactions: the magnitude of the problem. J Allergy Clin Immunol 1984; 74(4 Pt 2)555–557
   PubMed Web of Science ®Google Scholar
• Johnson J A, Bootman J L. Drug-related morbidity and mortality: a cost of illness model. Arch Intern Med 1995; 155: 1949–1956
   PubMed Web of Science ®Google Scholar
• Johnson R E, Chutuape M A, Strain E C, Walsh S L, Stitzer M L, Bigelow G E. A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. New England Journal of Medicine 2000; 343: 1290–1297
   PubMed Web of Science ®Google Scholar
• Joint United Nations Programme on HIV AIDS, World Health Organization. AIDS Epidemic Update. 2000
   Google Scholar
• Justice A., Chang C. H., Fusco J. et al. Extrapolating long-term HIV AIDS survival in the post HAART era. Abs. 1158. Interscience Conference on Antimicrobial Agents and Chemotherapy. 1999
   Google Scholar
• Karch F E, Lasagna L. Adverse drug reactions. A critical review. JAMA 1975; 234(12)1236–1241
   PubMed Web of Science ®Google Scholar
• Kasper C. Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies. Ann Hematol 2001; 80: 319–329
   PubMed Web of Science ®Google Scholar
• Kerkhof S C, de Dooelder P. F., Harinck H I, Stricker B H. Liver damage attributed to the use of disulfiram. Ned Tijdschr Geneeskd 1995; 18: 2378
   Google Scholar
• Kershenobich D, Henonin C H. Viral dynamics in hepatitis C. Isr Med Assoc J 2001; 3(5)360–363
   PubMed Web of Science ®Google Scholar
• Kertznus J, Molina E G, Regev A, Schiff E R. Combination therapy for HCV affects the [abs. 1217] HIV viral load in patients receiving highly active entiretroviral therapy (HAART). Abs. 1217, Hepatology 2003; 38(Suppl. 1)744A
   Google Scholar
• Kinsell L, Harper H A, Barton H C. Rate of disappearance from plasma of intravenously administered methionine in patients with liver damage. Science 1947; 106: 589–594
   Web of Science ®Google Scholar
• Kiyosawa K, Sodeyama T, Tanaka E. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–675
   PubMed Web of Science ®Google Scholar
• Klintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Science International 2001; 121: 65–69
   PubMed Web of Science ®Google Scholar
• Knutsen G. Komplikationer ved Antabusbehandking. Tidsskr Nor Laegeforen 1949; 69: 436
   PubMedGoogle Scholar
• Koopmans P P, van der Ven A J.A.M, Vree T B, van der Meer J WM. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic?. AIDS 1995; 9: 217–222
   PubMed Web of Science ®Google Scholar
• Kotler D P, Grunfeld C. Pathophysiology and treatment of the AIDS wasting syndrome. In: Volberding, P., Jacobson, M. A., eds. AIDS Clinical Review 1995 1996. Marcel Dekker, New York 1996; 229–275
   Google Scholar
• Kotler D P, Thierney A R, Wang J, Pierson R N. Magnitude of body cell mass depletion and the timing of death from waisting in AIDS. Am J Clin Nutr 1989; 50: 449
   Web of Science ®Google Scholar
• Kotler D P, Wang J, Pierson R N. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985; 42: 1225–1229
   Web of Science ®Google Scholar
• Kovac I, Merette C, Legault L, Dongier M, Palmour R M. WHO ISBRA Study on State and Trait Markers of Alcohol Use and Dependence Investigators. Evidence in an international sample of alcohol-dependent subjects of subgroups with specific symptom patterns of antisocial personality disorder. Alcohol Clin Exp Res 2002; 26(7)1088–1096
   PubMed Web of Science ®Google Scholar
• Kramer J. R., Giordano T., Souchek J., El-Serag H. The effect of hepatitis C coinfection on the risk of fulminant hepatic failure in patients with HIV in the HAART and pre-HAART eras m1213. 2004, abs. 10856, Digestive Disease Week
   Google Scholar
• Kreek M. J, Dodes L, Kane S. Long term methadone maintenance therapy. Effects on liver functions. Ann Intern Med 1972; 77: 598–600
   Google Scholar
• Kresina T F, Flexner C W, Sinclair J, Correia M A, Stapleton J T, Adeniyi-Jones S, Cargill V, Cheever L W. Alcohol use and HIV pharmacology. Aids Research and Human Retroviruses 2002; 18(11)757–770
   PubMed Web of Science ®Google Scholar
• Kristenson H. Long-term anti-abuse treatment of alcohol-dependent patients. Acta Psychiatr Scand (Suppl. 369) 1992, Suppl. 369: 41–45
   Google Scholar
• Lacoste-Rousillon C, Pouyanne P, Haramburn F, Miremont G, Begaud B. Incidence of serious adverse drug reactions in general practice: prospective study. Clin Pharmacol Ther 2001; 69: 458–462
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV HCV coinfection. Lancet 2001; 357: 280–281
   PubMed Web of Science ®Google Scholar
• Laskin U. Acyclovir. Rational Drug Ther 1984; 18: 1
   PubMedGoogle Scholar
• Laudat A, Blum L, Guechot J. Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with the CD4 cell counts. Eur J Endocrinol 1995; 133: 418–424
   PubMed Web of Science ®Google Scholar
• Lauer G M, Walker B D. Hepatitis C virus infection. N Engl J Med 2001; 345(1)41–52
   PubMed Web of Science ®Google Scholar
• Lauriault G, LeBelle M J, Lodge B A. Stability of methadone in four vehicles for oral administration. Am J Hosp Pharm 1991; 48(6)1252–1256
   PubMedGoogle Scholar
• Lavanchy D, Gavinio P. Hepatitis C. Can J Gastroenterol 2000; 14(Suppl. B)67B–76B
   Google Scholar
• Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–1205
   PubMed Web of Science ®Google Scholar
• Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733–1745
   PubMed Web of Science ®Google Scholar
• Leevy C M. Fatty liver: a study of 270 patients with biopsy proven fatty liver and a review of the literature. Medicine 1962; 41: 249–276
   PubMed Web of Science ®Google Scholar
• Lelbach W K. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann NY Acad Sci 1975; 252: 85–105
   PubMed Web of Science ®Google Scholar
• Levin R A. Absence of drug induced hepatotoxicity in heroin and metamphetamine users. Gastroenterology 1969; 56: 1217
   Web of Science ®Google Scholar
• Liaw Y F, Leung N W.Y, Chang T T. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172–180
   PubMed Web of Science ®Google Scholar
• Lieber C S. Hepatic, metabolic, and nutritional disorders of alcoholism: from pathogenesis to therapy. Crit Rev Clin Lab Sci 2000; 37(6)551–584
   PubMed Web of Science ®Google Scholar
• Lieber C S. Molecular basis and metabolic consequences of ethanol metabolism. International Handbook of Alcohol Dependence and Problems, N Heather, T J Peters, T. Stockwell. John Wiley & Sons, New York 2001; 75–102
   Google Scholar
• Lieber C S, DeCarli L M, Rubin E. Sequential production of fatty liver, hepatitis and cirrhosis in sub-human primates fed ethanol with adequate diets. Proc Natl Acad Sci USA 1975; 72: 437–441
   PubMed Web of Science ®Google Scholar
• Lieber C S, Weiss D, Grozmann R, Paronetto F, Schenker S. for the Veterans Affair Cooperative Study Group 391 I. Veteran Affairs Cooperative study of polyenylphosphosphatidylcholine in alcoholic liver disease: effects on drinking behaviour by nurse physician teams. Alcohol Clin Exp Res 2003a; 27(11)1–10
   PubMed Web of Science ®Google Scholar
• Lieber C S, Weiss D, Grozmann R, Paronetto F, Schenker S. (2003b). for the Veterans Affair Cooperative Study Group 391 II. Veteran Affairs Cooperative study of polyenylphosphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res, 27(11)11–18
   Web of Science ®Google Scholar
• Lifson A R, Rutherford G W, Iaffe H W. The normal history of human immunodeficiency virus infection. J Infect Dis 1988; 158: 1360–1367
   PubMed Web of Science ®Google Scholar
• Lischner M W, Alexander J F, Galambos J T. Natural history of alcoholic hepatitis: the acute disease. Am J Dig Dis 1971; 16: 481–494
   PubMedGoogle Scholar
• Loguercio C, Di Pierro M, Di Marino M P, Federico A, Disalvo D, Crafa E, Tuccillo C, Baldi F, del VecchioBlanco C. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol 2000; 35(3)296–301
   PubMed Web of Science ®Google Scholar
• Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B 2000. Summary of a Workshop. Gastroenterology 2001; 120: 1828–1853
   PubMed Web of Science ®Google Scholar
• Lonardo A, Loria P. Of liver, whisky and plants: a requiem for colchicine in alcoholic cirrhosis?. Eur J Gastroenterol Hepatol 2002; 14(4)355–358
   PubMed Web of Science ®Google Scholar
• Ma X, Baraona E, Goozner B G, Lieber C S. Gender differences in medium-chain dicarboxylic aciduria in alcoholic men and women. Am J Med 1999; 106(1)70–75
   PubMed Web of Science ®Google Scholar
• Macallan D C, Baldwin C, Jebb S A. Energy expenditure and wasting in HIV infection. N Engl J Med 1995; 333: 83–88
   PubMed Web of Science ®Google Scholar
• Maddocks S, Dwyer D. The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection. Paediatr Drugs 2001; 3(9)681–702
   PubMedGoogle Scholar
• Maddrey W. Safety of combination interferon alfa-2b ribavirin therapy in chronic hepatitis C-relapsed and treatment naive patients. Semin. Liver Dis 1999; 19: 67–75
   PubMed Web of Science ®Google Scholar
• Magnusson C R, Douglas R G, Jr, Betts R F. Double blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother 1977; 12: 493
   Web of Science ®Google Scholar
• Mahoney F G. Update on diagnosis, manegement, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351–366
   PubMed Web of Science ®Google Scholar
• Mansell C J, Locarnini S A. Epidemiology of hepatitis C in the East. Semin Liver Dis 1995; 15(1)15–32
   PubMed Web of Science ®Google Scholar
• Marcellin P. EASL international consensus conference on hepatitis C. J Hepatol 2000; 32: 98–112
   PubMedGoogle Scholar
• Martin P, Di Bisceglie A M, Kassianides C, Lisker-Melman M, Hoofnagle J H. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989; 97: 1559–1561
   PubMed Web of Science ®Google Scholar
• Martinez-Sierra C, Arizcorreta A, Diaz F, Roldan R, Martin-Herrera L, Perez-Guzman E, Giron-Gonzalez J A. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients co-infected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 15(4)491–498
   Google Scholar
• Mathers C D, Stein C, Ma Fat D. Global Burden of Disease 2000: Version 2. Methods and Results. World Health Organization, Geneva 2002
   Google Scholar
• Mauss S. HIV-associated lipodystrophy syndrome. AIDS 2000; 14(Suppl. 3)S197–S207
   PubMedGoogle Scholar
• Mauss S, Berger F, Schmutz G, Jacob B, Goelz J. A prospective controlled study assessing the treatment of chronic hepatitis C in patients with methadone maintenance. Hepatology 2003; 38(Suppl. 1)1215
   Google Scholar
• McClain C J, Cohen D A. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989; 3: 349–351
   Google Scholar
• McCusker M. Influence of hepatitis C status on alcohol consumption in opiate users in treatment. Addiction 2001; 96: 1007–1014
   PubMed Web of Science ®Google Scholar
• McMahon B J. Hepatocellular carcinoma and viral hepatitis. In: Wilson, R.A., ed. Viral Hepatitis. Marcel Dekker, New York 1997; 315–330
   Google Scholar
• McQuillan G M, Townsend T R, Fields H A, Carrol M, Leahy M, Polk B F. Seroepidemiology of hepatitis B virus infection in the United States. Am J Med 1989; 87(Suppl 3A)5S–10S
   PubMed Web of Science ®Google Scholar
• Mehta S, Moore R D, Graham N H.M. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11: 1665–1670
   PubMed Web of Science ®Google Scholar
• Mellor J, Holmes E C, Jarvis L M. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group. J Gen Virol 1995; 76(Pt 10)2493–2507
   Google Scholar
• Mellor J, Walsh E A, Prescott L E. Survey of type 6 group variants of hepatitis C virus in Southeast Asia by using a core-based genotyping assay. J Clin Microbiol 1996; 34(2)417–423
   PubMed Web of Science ®Google Scholar
• Mendenhall C L, Moritz T, Rouster S, Roselle G, Polito A, Quan S, DiNelle R K. Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275. Am J Gastroenterol 1993a; 88(7)1022–1026
   PubMed Web of Science ®Google Scholar
• Mendenhall C L, Moritz T, Chedid A, Polito A J, Quan S, Rouster S, Roselle G. Relevance of anti-HCV reactivity in patients with alcoholic hepatitis. VA cooperative Study Group #275. Gastroenterol Jpn 1993b; 28(Suppl 5)95–100
   PubMedGoogle Scholar
• Mezey E, Caballeria J, Mitchell M C, Pares A, Herlong H F, Rodes J. Effect of parenteral amino acid supplementation on short term and long term outcomes in severe alcoholic hepatitis a randomized controlled trial. Hepatology 1991; 14: 1090–1096
   PubMed Web of Science ®Google Scholar
• Miller J, Carr A, Smith D, Emery S, Law M G, Grey P, Cooper D A. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS 2000; 14: 2406–2407
   PubMed Web of Science ®Google Scholar
• Miller W R. Motivational interviewing: research, practice and puzzles. Addictive Behaviors 1996; 61(6)835–842
   Google Scholar
• Mitchell J E. Naltrexone and hepatotoxicity. Lancet 1986; 1: 1215
   PubMed Web of Science ®Google Scholar
• Mocroft A, Vella S, Benfield T L, Chiesi A, Miller V, Gargalianos P, Monforte A, Yust I, Bruun J N, Phillips A N, Lundgren J D. for the EuroSIDA Study group. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1988; 352: 1725–1730
   Google Scholar
• Mohamed A E, Kew M C, Groeneveld H T. Alcohol consumption as a risf factor for hepatocellular carcinoma in urban southern African blacks. Int J Cancer 1992; 51: 537–541
   PubMed Web of Science ®Google Scholar
• Mohsen A H, Easterbrook P J, Taylor C, Portmann B, Kulasegaram R, Murad S, Wiselka M, Norris S. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52(7)1035–1040
   PubMed Web of Science ®Google Scholar
• Mokhlesi B, Leikin J B, Murray P. Adult toxicology in critical care. Part II. Specific poisonings Chest 2003; 123(3)897–922
   PubMed Web of Science ®Google Scholar
• Molina P, McClain C, Valla D, Guidot D, Diehl A M, Lang C, Neuman M G. Molecular pathology and clinical aspects of alcohol induced tissue injury. Alcoholism: Clin Exper Res 2002; 26(1)120–128
   PubMed Web of Science ®Google Scholar
• Molyneux E, Ahern R, Baldwin B. Accidental ingestion of methadone. BMJ 1991; 303(6807)922–923
   PubMedGoogle Scholar
• Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharm 1998; 45(3)301–308
   PubMed Web of Science ®Google Scholar
• Moore R D, Chaisson R E. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13: 1933–1942
   PubMed Web of Science ®Google Scholar
• Motte S, Vincent J L, Gillet J B. Refractory hyperdynamic shock associated with alcohol and disulfiram. Am J Emerg Med 1986; 4(4)323–325
   PubMed Web of Science ®Google Scholar
• Mulligan K, Grunfeld C, Hellerstein M K, Neese R A, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 77: 956–962
   PubMed Web of Science ®Google Scholar
• Nagata S, Ishii H, Yokoyama H, Kato S, Moriya S, Maruyama K, Takahashi H, Tsuchiya M. Influence of HCV infection and its subtypes on clinical course of alcoholic liver disease. Gastroenterol Jpn 1993; 28(Suppl. 5)91–94
   PubMedGoogle Scholar
• Nakano F, Worner T M, Lieber C S. Perivenular fibrosis in alcoholic liver injury: ultrastructure and histologic progression. Gastroenterology 1982; 83: 777–785
   PubMed Web of Science ®Google Scholar
• Nalpas B, Driss E, Poe F. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol 1991; 12: 70
   PubMed Web of Science ®Google Scholar
• Naranjo C A, Bremner K E. Clinical pharmacology of serotonin-altering medications for decreasing alcohol consumption. Alcohol Alcohol (Suppl. 2) 1993, Suppl. 2: 221–229
   Google Scholar
• Neri S, Bruno C M, Abate G. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clinical Therapeutics 2002; 24(10)1627–1635
   PubMed Web of Science ®Google Scholar
• Neuman M G. Cytokines and inflamed liver. Clin Invest Med 1998; 23: 1–6
   Google Scholar
• Neuman M G. Cytokines and inflamed liver. Clin Biochem 1999; 33: 601–605
   Google Scholar
• Neuman M G. Apoptosis in disease of the liver. Crit Rev Clin Lab Sci 2001a; 38(2)109–166
   PubMed Web of Science ®Google Scholar
• Neuman M G. Mechanism of alcoholic liver disease. Clin Biochem 2001b; 34(3)163–167
   Web of Science ®Google Scholar
• Neuman M G. Cytokines in alcoholic liver. Alcohol Research & Health 2004; 27(4)313–322
   Google Scholar
• Neuman M G. Increased hepatotoxicity from acetaminophen in human hepatocytes pretreated with ethanol. Alcohol 2002; 27(2)89–98
   PubMedGoogle Scholar
• Neuman M G, Benhamou J P, Martinot M, Boyer N, Shear N H, Malkiewicz I, Katz G G, Suneja A, Singh S, Marcellin P. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clin Biochem 1999a; 32(7)537–545
   PubMed Web of Science ®Google Scholar
• Neuman M G, Benhamou J P, Malkiewicz I M, Ibrahim A, Valla D C, Martinot-Peignoux M, Asselah T, Bourliere M, Katz G G, Shear N H, Marcellin P. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 2002a; 9(2)134–140
   PubMed Web of Science ®Google Scholar
• Neuman M G, Brenner D A, Rehermann B, Taieb J, Chollet-Martin S, Cohard M, Garaud J J, Poynard T, Katz G G, Cameron R G, Shear N H, Gao B, Takamatsu M, Yamauchi M, Ohata M, Saito S, Maeyama S, Uchikoshi T, Toda G, Kumagi T, Akbar S M, Abe M, Michitaka K, Horiike N, Onji M. Mechanisms of alcoholic liver disease: cytokines. Alcohol Clin Exp Res 2001; 25(5)251S–253S
   Web of Science ®Google Scholar
• Neuman M, Bitton A, Glantz S. Tobacco industry strategies for influencing European Community tobacco advertising legislation. Lancet 2002b; 13: 1323–1330
   Google Scholar
• Neuman M G, Cameron R G, Shear N H, Feuer G G, Feuer G. Drug-induced apoptosis of skin cells and liver. In: Cameron, R.G., Feuer, G., eds. Handbook of Experimental Pharmacology: Apoptosis Modulation by Drugs. Springer Verlag, Heidelberg 1999b; 142: 344–355
   Google Scholar
• Neuman M G, Haber J A, Malkiewicz I M, Cameron R G, Katz G G, Shear N H. Ethanol signals for apoptosis in cultured skin cells. Alcohol 2002c; 26(3)179–190
   PubMed Web of Science ®Google Scholar
• Neuman M G, Katz G G, Malkiewicz I, Mathurin P, Tsukamoto H, Adachi M, Ishii H, Colell A, García-Ruiz C, Fernández-Checa J C, Casey C A. Alcoholic liver injury and apoptosis: synopsis of the symposium held at ESBRA 2001: 8th Congress of the European Society for Biomedical Research on Alcoholism. Alcohol, 2002d; 27(3)102–112
   Google Scholar
• Neuman M G, Malkiewicz I M, Phillips E J, Rachlis A, Ong D, Yeung E, Shear N H. Monitoring adverse drug reactions to sulphonamide antibiotics in human immunodeficiency virus infected individuals. Therapeutic Drug Monitoring 2002e; 24(4)728–736
   PubMedGoogle Scholar
• Neuman M G, Malkiewicz I M, Shear N H. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clinical Biochemistry 2000; 33(7)517–524
   PubMed Web of Science ®Google Scholar
• Noda K, Yoshihara H, Suzuki Y, Yamada Y, Kasahari A, Hayashi N, Fusamoto H. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma—its relationship to alcohol drinking and the age of transfusion. Alcohol Clin Exp Res 1996; 20(Suppl.)94A–100A
   PubMedGoogle Scholar
• Notermans D W, Jurriaans S, de Wolf F. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS 1998; 12: 167–173
   PubMed Web of Science ®Google Scholar
• Ntakarutimana V, Delaporte E, Pollet D, Demedts P, Scharpe S. Seroprevalence of hepatitis C virus in outpatients of health care services in Burundi. Ann Soc Belg Med Trop 1995; 75(4)283–290
   PubMedGoogle Scholar
• Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, Ito S, Fujiwara K. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91(7)1374–1379
   PubMed Web of Science ®Google Scholar
• Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K, Yamada Y, Abe H. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29(11)1039–1043
   PubMed Web of Science ®Google Scholar
• Oliver C. J., Rose A., Blagojevic N., Dwyer R., Gold D., Allen H. J. Total body protein status of males infected with the human immunodeficiency virus. In:. Human Body Composition, K. Ellis, G. Eastman. Plenum Press, New York 2003; 197–201
   Google Scholar
• Olkkola K T, Hamunen K, Maunuksela E L. Clinical Pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin Pharmacokinet 1995; 28(5)385–404
   PubMed Web of Science ®Google Scholar
• Oshita M, Hayashi N, Kasahara A, Hagiwara H, Mita E, Naito M, Katayama K, Fusamoto H, Kamada T. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20(5)1115–1120
   PubMed Web of Science ®Google Scholar
• Ott M, Fischer H, Polat H. Bioelectrical impedance analysis as a predictor of survival in patients with human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 20–25
   PubMedGoogle Scholar
• Ozdemir V, Kalow W, Tand B K. Evaluation of the genetic component of variabiliy in CYP 3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373–388
   PubMedGoogle Scholar
• Palella F J, Delaney K M, Moorman A C. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–860
   PubMed Web of Science ®Google Scholar
• Palenicek J P, Graham N M, He Y D. Weight loss prior to clinical AIDS as a predictor of survival. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10: 366–373
   PubMedGoogle Scholar
• Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. 1998, http://www.aidsinfo.nih.gov/guidelines
   Google Scholar
• Pares A, Barera J, Caballeria J. Hepatitis C antibodies in chronic alcoholic patients. Association with severity of liver injury. Hepatology 1990; 12: 1225
   Google Scholar
• Parker T H, Marshall J P, Roberts R K. Effect of acute alcohol ingestion on plasma pyridoxal 5′-phosphate. Am J Clin Nutr 1979; 32: 1246–1252
   PubMed Web of Science ®Google Scholar
• Patterson J L, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12(6)1139–1146
   PubMedGoogle Scholar
• Perez-Olmeda M, Garcia-Saramego J, Soraino V. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS 2000; 14: 212
   PubMed Web of Science ®Google Scholar
• Perronne C., Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel F., Morand P. et al. Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon-alfa-2b plus ribavirin vs interferon alfa- 2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-Infected patients. Abstract 117LB. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA February, 2004; 8–11
   Google Scholar
• Pesman C. Side effects may include death. Esquire. 2003; November: 82–91
   Google Scholar
• Pessoa M, Terrault N A, Ferrell L D, Detmer J, Kolberg J, Collins M L, Viele M, Lake J R, Roberts J P, Ascher N L, Wright T L. Hepatitis following liver transplantation: the role of the known and unknown viruses. Liver Transplantation and Surgery 1998; 4: 461–468
   PubMedGoogle Scholar
• Pessoa M, Terrault N A, Ferrell L D, Kim J P, Kolberg J, Detmer J, Collins M L, Yun A, Viele M, Lake J R, Roberts J P, Ascher N L, Wright T L. Hepatitis G virus in patients with cryptogenic liver disease undergoing liver transplantation. Hepatology 1997; 25: 1266–1270
   PubMed Web of Science ®Google Scholar
• Petitjean S, Stohler R, Deglon J J. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug & Alcohol Dependence 2001; 62: 97–104
   PubMed Web of Science ®Google Scholar
• Petri N M, Bickel W, Piasecki D, March L A, Badger G J. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J of Addic 2000; 9: 265–269
   PubMed Web of Science ®Google Scholar
• Pompidou A, Delsaux M C, Telvi L. Isoprinosine and imuthiol, two potentially active compounds in patients with AIDS-related complex symptoms. Cancer Res 1985; 45(9 Suppl.)4671S–4673S
   Web of Science ®Google Scholar
• Piscitelli S C, Burstein A H, Chaitt D. Indinavir concentrations and St John's wort. Lancet 2000; 355(9203)547–548
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. for the OBSVIRC, METAVIR, CLINVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825–832
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, Benhamou Y, Opolon P, Cacoub P, Bedossa P. Natural history of HCV infection. Baillieres Best Pract Res Clin Gastroentero 2000a; l 14(2)211–228
   Web of Science ®Google Scholar
• Poynard T, McHutchison J, Davis G L, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000b; 32(5)1131–1137
   PubMed Web of Science ®Google Scholar
• Prakash O, Mason A, Luftig R B. Bautista AP Hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infections in alcoholics. Front Biosci 2002; 1(7)e286–e300
   Google Scholar
• Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Perinatal HIV Guidelines Working Group. January 24, 2001, Available at:http://www.aidsinfo.nih.gov accessed February 14,2001
   Google Scholar
• Puffer R, Griffith G W. Patterns of Urban Mortality. Pan American Health Organization, Scientific Publication No. 151, Washington, DC 1967
   Google Scholar
• Qaqish R B, Fisher E, Rublein J, Wohl D A. HIV-associated lipodystrophy syndrome. Pharmacotherapy 2000; 20(1)13–22
   PubMed Web of Science ®Google Scholar
• Rachlis A R, Zarowny D P. for the Canadian HIV Trials Network Working Group. Guidelines for antiretroviral therapy for HIV infection. Can Med Assoc J 1998; 158(4)496–505
   PubMed Web of Science ®Google Scholar
• Ravitch J R, Sadler B M, McDowell J A, Walsh J S.. In vivo and in vitro studies of the potential for drug interactions involving the antiretroviral 1592 in humans. 5th Conference of Retroviruses and Opportunistic Infections. 1998
   Google Scholar
• Reddy K R, Hoofnagle J H, Tong M J, Lee W M, Pockros P, Heathcote E J. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30: 787–793
   PubMed Web of Science ®Google Scholar
• Reddy K R, Wright T L, Pockros P J, Shiffman M, Everson G, Reindollar R. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33(2)433–438
   PubMed Web of Science ®Google Scholar
• Rehm J, Room R, Graham K, Monteiro M, Gmel G, Sempos C T. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease—an overview. Addiction 2003a; 98(10)1209–1228
   PubMedGoogle Scholar
• Rehm J, Room R, Monteiro M, Gmel G, Graham K. (in press) Alcohol. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Due to Selected Major Risk Factors, M Ezzati, A D Lopez, A Rodgers, C JL Murray. WHO, Geneva
   Google Scholar
• Rehm J, Room R, Monteiro M, Gmel G, Graham K. Alcohol as a risk factor for global burden of disease. European Addiction Research 2003b; 9(4)157–164
   PubMed Web of Science ®Google Scholar
• Reines E D, Gross P A. Antiviral agents. Med Clin North Am 1988; 72: 691
   PubMed Web of Science ®Google Scholar
• Renault P F, Hoofnagle J H. Side effects of alpha interferon. Semin Liver Dis 1989; 9(4)273–277
   PubMed Web of Science ®Google Scholar
• Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998; 93(9)1385–1392
   PubMed Web of Science ®Google Scholar
• Ristig M B, Crippin J, Aberg J A, Powderly W G, Lisker-Melman M, Kessels L, Tebas T. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus hepatitis B virus-coinfected individuals for whom interferon-–a and lamivudine therapy have failed. J Infect Dis 2002; 186: 1844–1847
   PubMed Web of Science ®Google Scholar
• Rockstroh J K. Hepatitis C and HIV co-infection. Current aspects of therapy. MMW Fortschr Med 2002; 9(Suppl. 1)30–32
   Google Scholar
• Rockstroh J K, Thiesen A, Kaiser R, Sauerbruch T, Spengler J. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV co-infected heamophiliacs. AIDS 1998; 12: 829–890
   PubMedGoogle Scholar
• Romeo R, Rumi M G, Donato M F, Cargnel M A, Vigano P, Mondelli M, Cesana B. Hepatitis C is more severe in drug users with human immunodeficiency virus infection. J Viral Hepat 2000; 7: 297–301
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Grande L, Nogales M C. Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. Dig Liver Dis 2001; 33: 698–702
   PubMedGoogle Scholar
• Rosenblate H J, Einstein R, Baldwin D, Homes A W. Non viral hepatitis in drug addicts. Arch Patol 1973; 95: 18–21
   PubMedGoogle Scholar
• Rosman A S, Waraich A, Galvin K. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol 1996; 91: 498–505
   PubMed Web of Science ®Google Scholar
• Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217–242
   PubMed Web of Science ®Google Scholar
• Rouanet I, Peyriere H, Mauboussin J M, Terrail N, Vincent D. Acute clinical hepatitis by immune restoration in a human immunodeficiency virus hepatitis B virus co-infected patient receiving antiretroviral therapy. Eur J Gastroenterol Hepatol 2003; 15(1)95–97
   PubMed Web of Science ®Google Scholar
• Rutschmann O T, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin L H. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177: 783–785
   PubMed Web of Science ®Google Scholar
• Sabin C A, Telfer P, Phillips A N, Bhagani S, Lee C A. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Diseas 1997; 175: 164–168
   PubMed Web of Science ®Google Scholar
• Sampietro M, Tavazzi D, Martinez di Montemuros F, Cerino M, Zatelli S, Lunghi G, Orlandi A, Fargion S, Fiorelli G, Cappellini M D. TT virus infection in adult beta-thalassemia major patients. Haematologica 2001; 86(1)39–43
   PubMed Web of Science ®Google Scholar
• Sawada M, Takada A, Takase S, Takada N. Effects of alcohol on the replication of hepatitis C virus. Alcohol Alcohol (Suppl. 1B) 1993, Suppl. 1B: 85–90
   Google Scholar
• Schaefer M, Schmidt F, Folwazczny C. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443–451
   PubMed Web of Science ®Google Scholar
• Schalm S W, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562–568
   PubMed Web of Science ®Google Scholar
• Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting: a randomized clinical trial. Ann Intern Med 1996; 125: 873–882
   PubMed Web of Science ®Google Scholar
• Schiff E R. Hepatitis C and alcohol. Hepatology 1997; 26(3 Suppl. 1)39S–42S
   Web of Science ®Google Scholar
• Seef L B. Hepatitis in the drug abuser. Med Clin N Am 1975; 59: 843
   PubMed Web of Science ®Google Scholar
• Seeff L, Buskell-Bales Z, Wright E. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906–1911
   PubMed Web of Science ®Google Scholar
• Seeff L B, Hoofnagle J H. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36(Suppl. 1)S1–S2
   Google Scholar
• Seitz H K, Egerer G, Simanowski U A, Waldherr R, Eckey R, Agarwal D P, Goedde H W, von Wartburg J P. Human gastric alcohol dehydrogenase activity: effect of age, sex, and alcoholism. Gut 1993; 34: 1433–1437
   PubMed Web of Science ®Google Scholar
• Sherman K E, Freeman S, Harrison S, Andron L. Prevalence of antibody to hepatitis C virus in patients infected with the human immunodeficiency virus. J Infect Dis 1991; 163: 414–415
   PubMed Web of Science ®Google Scholar
• Servoss J, Kitch D, Andersen J, Robbins G K, Reisler R B, Chung R T. Predictors of antiretroviral-related hepatotoxicity in the adults AIDS clinical trials group (AACTG). Hepatology 2003; 38(Suppl. 1)abs.70
   Google Scholar
• Shimanaka K, Tsutsumi M, Sawada M, Tsuchishima M, Urashima S, Ueshima M, Kawahara H, Takase S. Clinicopathological study of chronic hepatitis induced by alcohol with or without hepatitis G virus. Alcoholism Clin Exp Res 1999; 24(3 suppl)29–33
   Google Scholar
• Simmonds P, Alberti A, Alter H J, Bonino F, Bradley D W, Brechot C. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19(5)1321–1324
   PubMed Web of Science ®Google Scholar
• Single E, Robson L, Rehm J, Xie X. Morbidity and mortality attributable to alcohol, tobacco, and illicit drug use in Canada. American Journal of Public Health 1999; 89(3)385–390
   PubMed Web of Science ®Google Scholar
• Single E., Robson L., Xie X., Rehm J. The Cost of substance Abuse in Canada. Ottawa. Canadian Centre on Substance Abuse, Ontario 1996b
   Google Scholar
• Snell L D, Glanz J, Tabakoff B, WHO ISBRA Study on State and Trait Markers of Alcohol Use and Dependence Investigators. Relationships between effects of smoking, gender, and alcohol dependence on platelet monoamine oxidase-B: activity, affinity labeling, and protein measurements. Alcohol Clin Exp Res 2002; 26(7)1105–1113
   PubMed Web of Science ®Google Scholar
• Soriano V, Bravo R, Garcia-Samaniego J, Castilla J, Gonzalez J, Castro A, Llibre J M. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. Hepatitis HIV Spanish Study Group. AIDS 1997; 11: 400–401
   Google Scholar
• Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, Martinez-Odriozola P. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23: 585–591
   PubMed Web of Science ®Google Scholar
• Soto B, Sanchez-Quijano A, Rodrigo L, del Olrno J A, Garcia-Bengoechea M. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. Journal of Hepatology 1997; 26: 1–5
   PubMed Web of Science ®Google Scholar
• Spengler U, Lichterfeld M, Rockstroh J K. Antiretroviral drug toxicity: a challenge for hepatologist?. J Hepatol 2002; 36: 283–294
   PubMed Web of Science ®Google Scholar
• Spinetti A, Puito M, Donato F. Increase of liver related in hospital mortality in a cohort of Italian seropositives after introduction of HAART: role of hepatitis virus coinfections. Abstract TuPe3184, Presented at the XIII International AIDS Conference, Durban, South AfricaSouth Africa, July 2000., 2000
   Google Scholar
• Sproule B A. Substance abuse. Pharmacology Self-Assessment Program4th, B A Mueller, K E Bertch, T S Dunsworth, S C Fagan, M S Hayney, M B O’Connell, G T Schumock, D F Thompson, J E Tisdale, D M Witt, B J. Zarowitz. American College of Clinical Pharmacy, Kansas City 2002; 133–166
   Google Scholar
• Staples C T, Rimland D, Dudas D. Hepatitis C in the human immunodeficiency virus Atlanta Veterans Affairs Medical Center cohort study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29: 150–154
   PubMed Web of Science ®Google Scholar
• Starr S E, Fletcher C V, Spector S A. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999; 341(25)1874–1881
   PubMed Web of Science ®Google Scholar
• Stein M D, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001; 61: 211–215
   PubMed Web of Science ®Google Scholar
• Stephens R S, Roffman R A, Simpson E E. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol 1994; 62: 92–99
   PubMed Web of Science ®Google Scholar
• Stittman U, Ockenga J, Selberg O. Incidence and prognostic value of malnutrition and wasting in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 239–246
   PubMedGoogle Scholar
• Strader D B, Wright T, Thomas D L, Seeff L B. AASLD Practice Guideline: Diagnosis, Management, and Treatment of Hepatitis C. American Association for the Study of Liver Diseases, available at www.interscience.wiley.com
   Google Scholar
• Sulkowski M S, Mast E E, Seeff L B, Thomas D L. Hepatitis C virus as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000a; 30: S77–S84
   PubMed Web of Science ®Google Scholar
• Sulkowski M S, Thomas D L, Chaisson R E, Moore R D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000b; 283: 74–79
   PubMed Web of Science ®Google Scholar
• Sun F, Tsuritani I, Yamada Y. Contribution of genetic polymorphisms in ethanol-metabolizing enzymes to problem drinking behavior in middle-aged Japanese men. Behav Genet 2002; 32(4)229–236
   PubMed Web of Science ®Google Scholar
• Sundar K, Suarez M, Banogon P E, Shapiro J M. Zidovuline-induced fatal lactic acidosis and hepatic failure in patients with aquaired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med 1997; 25: 1425–1430
   PubMed Web of Science ®Google Scholar
• Svensson C K, Cowen E W, Gaspari A A. Cutaneous drug reactions. Pharmacol Rev 2000; 53: 357–379
   Web of Science ®Google Scholar
• Sylvestre D L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Dependence 2002; 67: 117–123
   PubMed Web of Science ®Google Scholar
• Szabo G, Verma B, Catalano D. Selective inhivition of antigen-specific T lymphocytes proliferation by acute ethanol exposure. The role of impaired monocyte antigen-presentation capacity and mediator production. J Leuk Biol 1993; 54: 534–544
   Google Scholar
• Takase S, Takada N, Sawada M, Tsutsumi M, Takada A. Relationship between alcoholic liver disease and HCV infection. Alcohol Alcohol 1993, Suppl. 1A: 7–84
   Google Scholar
• Tanji N, Tanji K, Kambham N, Markowitz G S, Bell A, D’Agati V D. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32: 734–740
   PubMed Web of Science ®Google Scholar
• Terrault N A, Dailey P J, Ferrell L, Collins M C, Wilber J C, Urdea M S, Bhandari B N, Wright T L. Quantification and intrahepatic distribution of HCV RNA in whole livers. J Med Virol 1997; 51: 217–224
   PubMedGoogle Scholar
• The EASL Jury. EASL International Consensus Conference on Hepatitis. Consensus statement (short version). J Hepatol 2003; 38: 533–540
   Google Scholar
• The World Bank. World Development Report 1993. Investing in Health, Washington, DC. The World Bank, 75, 1993
   Google Scholar
• Thomas D L. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36(Suppl. 1)S201–S209
   Google Scholar
• Tong M J, El-Farra N S, Reikes A R. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–1466
   PubMed Web of Science ®Google Scholar
• Torriani F J, Rockstroh J, Rodriguez-Torres M, Lissen E, Gonzalez J, Lazzarin A, Carosi G. Final Results of APRICOT: a randomized, partially blinded, international trial evaluating peginterferon-alfa-2a-ribavirin versus interferon-alfa-2a-ribavirin in the treatment of HCV in HIV-HCV co-infection. Abstract 112, 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February, 8–112004
   Google Scholar
• Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Analytical Toxicology 1998; 22(6)430–434
   PubMed Web of Science ®Google Scholar
• Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797–1801
   PubMed Web of Science ®Google Scholar
• Tural C, Fuster D, Tor J, Ojanguren I, Sirera G, Ballesteros A, Lasanta J A, Planas R, Rey-Joly C, Clotet B. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003; 10(2)118–125
   PubMed Web of Science ®Google Scholar
• Vaillant G E. The alcohol dependent and drug dependent person. The New Havard Guide to Psychiatry, A M Nicoli. Cambridge: Havard University Press. 1988
   Google Scholar
• Vech R L, Lumeng L, Li T K. Vitamin B6 metabolism in chronic alcohol abuse. The effect of ethanol oxidation on hepatic pyridoxal 5′-phosphate metabolism. J Clin Invest 1975; 55: 1026–1032
   PubMed Web of Science ®Google Scholar
• Verbaan H, Andersson K, Eriksson S. Intravenous drug abuse–the major route of hepatitis C virus transmission among alcohol-dependent individuals?. Scand J Gastroenterol 1993; 28(8)714–718
   PubMed Web of Science ®Google Scholar
• Verheist D, Monge M, Meynard J L, Fouqueray B, Mougenot B, Girard P M, Ronco P. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331–1333
   PubMed Web of Science ®Google Scholar
• Volberding P. Evidence-based recommendation on the management of HIV AIDS: an Experts' Consensus meeting to develop treatment guidelines for developed nations. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 1–17
   PubMedGoogle Scholar
• Von Roenn J H, Armstrong D, Kotler D P. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994; 121: 393–399
   PubMed Web of Science ®Google Scholar
• Walensky R P, Goldberg J H, Daily J P. Anaphylaxis after rechallenge with abacavir. AIDS 1999; 13(8)999–1000
   PubMed Web of Science ®Google Scholar
• Walsh K, Alexander G. Alcoholic liver disease. Postgrad Med J 2000; 76(895)280–286
   PubMed Web of Science ®Google Scholar
• Warren K J, Boxwell D E, Kim N Y, Drolet B A. Nevirapine associated Steven-Johnson syndrome. Lancet 1999; 351: 567
   Web of Science ®Google Scholar
• Wasserman S, Yahr M D. Choreic movements induced by the use of methadone. Arch Neurol 1980; 37(11)727–728
   PubMedGoogle Scholar
• Weinroth S E, Parenti D M, Simon G L. Wasting syndrome in AIDS: pathophysiologic mechanisms and approaches. Infect Agents Dis 1995; 4: 76–94
   PubMedGoogle Scholar
• Weiss K. Safety profile of interferon alpha therapy. Semin Oncol 1998; 25(1 Suppl.)9–13
   PubMed Web of Science ®Google Scholar
• Westin J, Lagging L M, Spak F, Aires N, Svensson E, Lindh M, Dhillon A P. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2000; 9: 235–241
   Web of Science ®Google Scholar
• Whitley R J, Soong S J, Hirsh M S. Herpes simplex encephalitis, viradabine therapy and diagnostic problems. N Engl J Med 1981; 304: 313–316
   PubMed Web of Science ®Google Scholar
• Wiley T E, McCarthy M, Breide L, McCarthy M, Layden T J. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28: 805–809
   PubMed Web of Science ®Google Scholar
• Wood A. Androgens in men: uses and abuses. N Engl J Med 1996; 334: 707–714
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). International Classification of Diseases. Injuries, and Causes of Death. Ninth revision. World Health Organization, GenevaSwitzerland 1977; I and II
   Google Scholar
• World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems10th Revision. World Health Organization, GenevaSwitzerland 1992
   Google Scholar
• World Health Organization (WHO). United Nations Children's Fund (UNICEF), and the International Council for the Control of Iodine Deficiency Disorders. WHO, GenevaSwitzerland 1993; 1–7, Global prevalence of Iodine Deficiency Disorders.” Micronutrient Deficiency Information System Working Paper No. 1.
   Google Scholar
• World Health Organization (WHO) and the United Nations Children's Fund (UNICEF). Global Prevalence of Vitamin A Deficiency. Micronutrient Deficiency Information System Working Paper no. 2. WHO, GenevaSwitzerland, WHO 1995; 5
   Google Scholar
• World Health Organization (WHO). The World Health Report 1997. Conquering Suffering, Enriching Humanity. GenevaSwitzerland 1997; 51
   Google Scholar
• World Health Organization (WHO). Hepatitis C. Weekly Epidemiol Rec 1997b; 72(10)65–69
   PubMedGoogle Scholar
• World Health Organization (WHO). Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat 1999; 6(1)35–39
   Google Scholar
• World Health Organization (WHO). The World Health Report. Health Systems: Improving Performance. Geneva, Switzerland: World Health Organization. 2000
   Google Scholar
• World Health Organization (WHO). World Health Report 2002. Reducing Risks, promoting Healthy life. World Health Organization, GenevaSwitzerland 2002
   Google Scholar
• Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. from. 2001, http://www.aidsinfo.nih.gov accessed December 14
   Google Scholar
• Wu C H, Henry J A. Deaths of heroin addicts starting on methadone maintenance. Lancet 1990; 335(8686)424
   PubMed Web of Science ®Google Scholar
• Wu N. Preliminary research on the co-infection of human immunodeficiency virus and hepatitis virus in intravenous drug users. Chinese Med J [in English] 2003; 116(9)1318–1320
   PubMed Web of Science ®Google Scholar
• Zarski J P, Thelu M A, Moulin C, Rachail M, Seigneurin J M. Interest of the detection of hepatitis C virus RNA in patients with alcoholic liver disease. Comparison with the HBV status. J Hepatol 1993; 17(1)10–14
   Google Scholar
• Zeuzem S, Feinman S V, Rasenack J, Heathcote E J, Lai M Y, Gane E. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343(23)1666–1672
   PubMed Web of Science ®Google Scholar
• Zhou S, Terrault N A, Ferrell L, Hahn J A, Lau J Y.N, Simmonds P, Roberts J P, Lake J R, Ascher N L, Wright T L. Severity of disease in liver transplant recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996; 24: 1041–1046
   PubMedGoogle Scholar
• Zou S, Tepper M, El Saadany S, Aadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol 2000; 14(7)575–580
   PubMedGoogle Scholar
• Zimmerman H J. Hepatotoxic effects of ethanol. In. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver2nd. Lippincott Williams and Wilkinsm, Philadelphia 1999; 147–177
   Google Scholar
• Zimmerman H J, Lowry C F, Uyeyama K, Reiser R. Infectious hepatitis: clinical and laboratory features of 295 cases. Am J Med Sci 1947; 213: 395–409
   PubMed Web of Science ®Google Scholar
• Zylberberg H, Fontaine H, Thepot V, Nalpas B, Brechot C, Pol S. Triggering of acute alcoholic hepatitis by alpha-interferon therapy. J Hepatol 1999; 30(4)722–725
   PubMed Web of Science ®Google Scholar